To report the experience with the use of alectinib in refractory ALK-positive large B-cell lymphoma (ALK+ LBCL) and its implications for treatment strategies.
Key Findings:
ALK+ LBCL is a rare and aggressive lymphoma with poor prognosis and limited treatment options, highlighting the need for novel therapies.
Alectinib resulted in a complete metabolic response after previous treatments failed, demonstrating its potential efficacy.
The patient maintained a sustained complete metabolic response for 4 years post-allogeneic stem cell transplant, indicating long-term benefits.
Interpretation:
Alectinib may serve as an effective bridging therapy for refractory ALK+ LBCL, potentially improving outcomes for patients awaiting allogeneic stem cell transplantation.
Limitations:
The study is based on a single case report, limiting generalizability.
Further prospective studies are needed to validate findings and include diverse patient demographics.
Conclusion:
Alectinib demonstrated excellent tolerability and efficacy in this case, suggesting potential for broader application in refractory ALK+ LBCL. Future research should explore its use in larger cohorts and different treatment settings.
